ReliantHeart technology is setting a new standard of care for heart patients and having a large impact on patient quality of life. I’m gratified to be able to assist the company in moving forward.
Houston, Texas (PRWEB) October 07, 2015
ReliantHeart, Inc. the manufacturer of the HeartAssist5® Left Ventricular Assist Device (LVAD) has appointed S. Russel Craig of Spectral Platforms, and Michael Ward of Wrenward Medical Systems to its Board of Directors.
Mr. Craig has both substantial line management and consulting experience. Currently he is Executive Vice President of Strategic Relationships and Operations, and a member of the Board of Spectral Platforms. Over his career, he has held multiple other Board positions, including Chipsoft, when it was sold to Intuit in 1993, in a transaction valued at over $250 Million. His experience includes negotiating many significant strategic partnerships, acquisitions and divestitures.
For more than 28 years, Michael Ward has been an innovator and thought leader in the healthcare industry, helping to define best practice, optimize work flow, product enhancements, supply chain software systems, sales leadership, and ground up medical device development and successful commercialization.
Craig and Ward bring seasoned judgment to ReliantHeart to enhance the company’s performance necessary to create shareholder value. According to Craig, “ReliantHeart technology is setting a new standard of care for heart patients and having a large impact on patient quality of life. I’m gratified to be able to assist the company in moving forward.”